Analyst firms · Leerink Partners · GOSS
Leerink Partners GOSS price target and rating history
Gossamer Bio Inc. (GOSS) · Health Care
Leerink Partners rates Gossamer Bio Inc. (GOSS) Outperform with a $1 price target, as of its latest action on Jul 28, 2026. It has published 4 rating actions on GOSS since August 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a GOSS price target in the last 12 months, the median target is $1. Leerink Partners's target matches it.
- Current rating
- Outperform
- Price target
- $1
- Median target, all firms
- $1
- Actions on GOSS
- 4
Leerink Partners price target on GOSS
Every Leerink Partners rating on GOSS
- Jul 28, 2026
- Feb 24, 2026
- Nov 9, 2021
- Aug 10, 2021
How other firms rate GOSS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Chardan Capital Markets | Buy | $160 | Oct 13, 2026 |
| Leerink Partners | Outperform | $1 | Jul 28, 2026 |
| Cantor Fitzgerald | Neutral | Mar 23, 2026 | |
| Wedbush | Neutral | $1 | Feb 24, 2026 |
| Barclays | Equal Weight | $0.30 | Feb 24, 2026 |
Questions about Leerink Partners and GOSS
- What is Leerink Partners's price target for GOSS?
- Leerink Partners's latest stated price target for Gossamer Bio Inc. (GOSS) is $1, from its action on Jul 28, 2026.
- What is Leerink Partners's rating on GOSS?
- Leerink Partners rates GOSS Outperform, a bullish rating, as of Jul 28, 2026.
- When did Leerink Partners last change its view on GOSS?
- On Jul 28, 2026, Leerink Partners upgrades to Outperform from Market Perform, price target $1.
- How does Leerink Partners's GOSS target compare with other analysts?
- Across 4 firms with a GOSS price target in the last 12 months, the median target is $1. Leerink Partners's target matches it.
More GOSS rating histories
All Leerink Partners ratingsGOSS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.